Thursday, February 19, 2026 2/19/2026

Molecular understanding of leukemic bone marrow cytokine-Ras signals and metabolic dependence

Award Number: R01CA187318
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2015
PERIOD OF PERFORMANCE END DATE: 12/31/2026

Group Awards By:

View Award Description

Molecular understanding of leukemic bone marrow cytokine-Ras signals and metabolic dependence - PROJECT SUMMARY/ABSTRACT Childhood Acute Lymphoblastic Leukemia (ALL) is a disease of the bone marrow with expansion of immature cells and treated with non-specific chemotherapy. ALL remains one of the leading causes of cancer death in persons <20 years old. The developmental origin of T cell ALL (T-ALL) is and profoundly impacts the clinic. Genetic mutations pointed aberrant Ras signals with causal role in 50% of T-ALL, but how such aberrant signals impact developmental trajectories in T-ALL is not known. Similarly, it is by and large unknown how to effectively inhibit aberrant Ras signals. During 1R01CA187318 we uncovered a new molecular paradigm in Ras signaling; Oncogenic Ras mutations (KRasG12D) and overexpression of the Ras activator RasGRP1 drive two very distinctive leukemic Ras signals. In the progress report with our new RoLoRiG/Mx1CRE mouse model, we show that these two aberrant Ras signals both induce abnormal hematopoiesis, but with opposing stem cell features. Capitalizing on our quantitative, multiplex flow cytometry platform we determined that Ras and RasGRP1 frequently connect to PI3K (phosphoinositide 3-kinase)-AKT/mTOR signaling in T-ALL. Next, we performed four extensive synthetic lethality screens with PI3K inhibitors to identify effective combination therapy in T-ALL. We confirmed ten predicted combination therapies with small molecule inhibitors and the PI3K inhibitor GDC0941 with tubulin inhibitor Vincristine yields broad synergy in five cancer types and in our preclinical mouse trials in vivo. The screens predict many metabolic targets, which remained unexplored. Our renewal focuses on understanding the connection between aberrant Ras-PI3K signals and cell metabolism with the goal of resolving the developmental origin of T-ALL and testing new combination therapies. We will determine the connections between Ras-PI3K signals and cell metabolism in our panel of 10 T-ALL cell lines by investigating six nutrient transporters (SLCs), identified in our screens (Aim 1). We will obtain mechanistic understanding of the signals, metabolic features, and hematopoietic composition and trajectories, as a function of leukemic Ras-PI3K signals with unprecedented resolution. We will continue efforts on RoLoRiG/Mx1CRE and KRasG12D/Mx1CRE mouse models that display completely opposite phenotypes in bone marrow stem cells (Aim 2). Lastly, we will obtain a comprehensive characterization of developmental-, biochemical- and metabolic- programs in pediatric T-ALL with single cell resolution. We will combine these efforts with preclinical trial to test the in vivo efficacy of PI3Kγ- and δ- inhibition, inhibition of SLC13A2 and SLC25A44, and combinations in our T-ALL/NGS platform (Aim 3). The synergistic aims, metabolic insights, new mouse models, patient sample-NSG pipeline, and innovative, single cell-resolution technology platforms (CyTOF, SCENITH, phospho-flow) will allow us to make significant contributions towards molecular understanding of T-ALL and precision medicine in cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $345,206 )
2026	2026	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Biology Research	000	10	2/11/2026	NON-COMPETING CONTINUATION	$345,206
														Subtotal = $345,206

Issue Date FY: 2025 ( Subtotal = $383,563 )
2025	2025	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Biology Research	000	9	12/13/2024	NON-COMPETING CONTINUATION	$345,206
2025	2025	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Biology Research	001	9	9/2/2025	NON-COMPETING CONTINUATION	$38,357
														Subtotal = $383,563

Issue Date FY: 2024 ( Subtotal = $364,384 )
2024	2024	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Biology Research	001	8	4/19/2024	NON-COMPETING CONTINUATION	$19,178
2024	2024	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Biology Research	000	8	12/21/2023	NON-COMPETING CONTINUATION	$345,206
														Subtotal = $364,384

Issue Date FY: 2023 ( Subtotal = $375,891 )
2023	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Biology Research	001	7	3/20/2023	NON-COMPETING CONTINUATION	$30,685
2023	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Biology Research	000	7	11/30/2022	NON-COMPETING CONTINUATION	$345,206
														Subtotal = $375,891

Issue Date FY: 2022 ( Subtotal = $383,563 )
2022	2022	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Biology Research	000	6	12/31/2021	COMPETING CONTINUATION	$383,563
														Subtotal = $383,563

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Biology Research	000	5	10/29/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $343,163 )
2019	2019	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Biology Research	000	5	6/26/2019	NON-COMPETING CONTINUATION	$343,163
														Subtotal = $343,163

Issue Date FY: 2018 ( Subtotal = $353,777 )
2018	2018	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 420	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Biology Research	000	4	6/11/2018	NON-COMPETING CONTINUATION	$353,777
														Subtotal = $353,777

Issue Date FY: 2017 ( Subtotal = $353,777 )
2017	2017	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Biology Research	000	3	6/22/2017	NON-COMPETING CONTINUATION	$353,777
														Subtotal = $353,777

Issue Date FY: 2016 ( Subtotal = $353,777 )
2016	2016	UNIVERSITY OF CALIFORNIA-SAN FRANCISCO	BOX 0812	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Biology Research	000	2	6/14/2016	NON-COMPETING CONTINUATION	$353,777
														Subtotal = $353,777

Issue Date FY: 2015 ( Subtotal = $353,777 )
2015	2015	UNIVERSITY OF CALIFORNIA-SAN FRANCISCO	BOX 0812	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Biology Research	000	1	7/1/2015	NEW	$353,777
														Subtotal = $353,777

Grand Total All Awards = $3,610,878

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Molecular understanding of leukemic bone marrow cytokine-Ras signals and metabolic dependence

Award Number: R01CA187318

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2015

PERIOD OF PERFORMANCE END DATE: 12/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer